The short answer
The trials suggest the effect lasts while you take it. In SURMOUNT-4, 89.5% of people who stayed on tirzepatide kept at least 80% of their weight loss, versus 16.6% of people switched to placebo. Whether to stay on is between you and your prescriber.1
Your prescriber decides about your medicine. Reviewed November 14, 2026.What people ask
Searched every month
- do you have to take ozempic forever590
- do you have to stay on ozempic forever480
- wegovy stopped working320
US Google searches a month, 12-month average to November 2026 (Google Ads Keyword Planner).
What the research says
The numbers, on average
- −7.9%more weight lost over 48 weeks by people who stayed on semaglutide, vs +6.9% regained on placebo (803 people)2
- 53.6%stopped within a year in a US study of 125,474 people3
- 50.3%of people with obesity stopped within 12 months, in a study of 20,2174
- Stayed on tirzepatide
- 89.5%
- Switched to placebo
- 16.6%
Diabetes changes the pattern
In the US study, 64.8% of people without type 2 diabetes stopped within a year, versus 46.5% of people with it. At 2 years, 72.2% overall had stopped.3
Cost is the top reason
In a study of 288 people who stopped, 47.6% named cost or insurance, 14.6% side effects and 11.8% shortages.5
Nutrients can run low on it
People taking GLP-1 medicines averaged 14.5 g of fiber and 863 mg of calcium a day in one intake study.6
What it means for meals
Either way, the plate matters
Close the fiber gap
Beans, lentils, oats and vegetables lift fiber whether you stay on or stop.
Calcium every day
Yogurt, milk, tofu and canned fish with bones add calcium.
Protein to protect muscle
The joint advisory pairs protein with strength training to keep muscle.7
Alma logs a meal from a photo, voice or text in about 10 seconds and shows protein and fiber for each meal.
Questions people ask
Is a GLP-1 a lifelong medicine?
The trials show weight returns on average after stopping, which is why many prescribers treat obesity as a long-term condition. Your prescriber decides with you.
Why do so many people stop?
Cost or insurance is the most common reason. In one study of 288 people who stopped, 47.6% named it, ahead of side effects and shortages.
What if it seems to stop working?
Weight loss slows for everyone over time. If progress stalls or reverses, talk to your prescriber before changing anything.
Sources
- Aronne et al. 2024. Continued tirzepatide vs placebo for weight maintenance: the SURMOUNT-4 trial. JAMA.
- Rubino et al. 2021. Continued vs withdrawn semaglutide for weight maintenance: the STEP 4 trial. JAMA.
- Rodriguez et al. 2025. Discontinuation and restarting of GLP-1 medicines in 125,474 US adults. JAMA Network Open.
- Do et al. 2024. GLP-1 medicine discontinuation among US adults with obesity. JAMA Network Open.
- Reasons people stop GLP-1 medicines: a study of 288 patients. PubMed Central, 2025.
- Dietary intake and nutrient gaps in adults taking GLP-1 medicines. PubMed, 2025.
- Nutritional priorities to support GLP-1 therapy for obesity: joint advisory of ACLM, ASN, OMA and The Obesity Society, 2025.
US Google searches a month, 12-month average to November 2026 (Google Ads Keyword Planner). Editorial standards
Alma does not give medical advice. Starting, stopping or changing a GLP-1 dose is a decision for your prescriber.
